MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ
32.97
-0.44
-1.32%
Opening 14:38 09/29 EDT
OPEN
33.07
PREV CLOSE
33.41
HIGH
33.23
LOW
32.47
VOLUME
260.24K
TURNOVER
6.83M
52 WEEK HIGH
36.08
52 WEEK LOW
24.95
MARKET CAP
1.76B
P/E (TTM)
33.41
1D
5D
1M
3M
1Y
5Y
Supernus Pharmaceuticals On Sept. 9 Was Awarded $132M Department Of Veterans Affairs Contract
https://sam.gov/opp/763949eb6dcd4345a15a5d5d16c0ad23/view
Benzinga · 09/12 18:11
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Supernus Pharmaceuticals (NASDAQ:SUPN) has had a great run on the share market with its stock up by a significant 21...
Simply Wall St. · 09/07 13:03
Supernus to Present at the 2022 Wells Fargo Healthcare Conference
ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that...
GlobeNewswire · 08/31 20:00
Supernus Pharmaceuticals Appears Ready for an Upside Breakout
Supernus Pharmaceuticals SUPN is a biopharmaceutical company that is involved in developing and commercializing products that treat central nervous system diseases. In this daily bar chart of SUPN, below, we can see that prices have largely moved in a sid...
TheStreet.com · 08/31 12:55
Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $38
Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $33 to $38.
Benzinga · 08/31 11:31
Piper Sandler Adjusts Price Target on Supernus Pharmaceuticals to $38 From $33, Reiterates Overweight Rating
Piper Sandler Adjusts Price Target on Supernus Pharmaceuticals to $38 From $33, Reiterates Overweight Rating
MT Newswires · 08/31 06:54
Insider Sell: Supernus Pharmaceuticals
Insider Sell: Supernus Pharmaceuticals
MT Newswires · 08/17 16:34
The past five years for Supernus Pharmaceuticals (NASDAQ:SUPN) investors has not been profitable
While not a mind-blowing move, it is good to see that the Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) share price...
Simply Wall St. · 08/11 12:59
More
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes treatments for epilepsy, migraine, attention deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. It is also developing a range of CNS product candidates, including potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced Parkinson's disease (PD).

Webull offers kinds of Supernus Pharmaceuticals Inc stock information, including NASDAQ:SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.